Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says

Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet